Zyclara (Imiquimod) cream, 3.75%

SKINmed

Volumn 8, Issue 4, 2010, Pages 227-229

  Gupta, Aditya K ^a,b   Cooper, Elizabeth A ^b   Abramovits, William ^c,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b MEDIPROBE RESEARCH INC   (Canada)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOQUINOLINE DERIVATIVE; IMIQUIMOD; IMMUNOLOGICAL ADJUVANT;

ACTINIC KERATOSIS; ARTICLE; CANADA; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; HUMAN; INTRADERMAL DRUG ADMINISTRATION; PATHOLOGY; UNITED STATES;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, CUTANEOUS; AMINOQUINOLINES; CANADA; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; HUMANS; KERATOSIS, ACTINIC; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 79952108990     PISSN: 15409740     EISSN: 17517125     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Aldara (imiquimod) cream, 5% [product monograph]. London, ON, Canada: Graceway Pharmaceuticals; March 04, 2009.
2. Aldara cream, 5% (imiquimod) [prescribing information]. Bristol, TN: Graceway Pharmaceuticals, LLC; April 2009.
3. Gaspari AA, Tyring SK, Rosen T. Beyond a decade of 5% imiquimod topical therapy. J Drugs Dermatol. 2009;8:467-474.
4. Zyclara (imiquimod) cream, 3.75% [product monograph]. London, ON, Canada: Graceway Pharmaceuticals; December 31, 2009.
5. Zyclara (imiquimod) cream, 3.75% [product monograph]. Bristol, TN: Graceway Pharmaceuticals, LLC; March 2010.
6. Swanson N, Abramovits W, Berman B, et al. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. J Am Acad Dermatol. 2010;62:582-590.
7. Hanke CW, Beer KR, Stockfleth E, et al. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles. J Am Acad Dermatol. 2010;62:573-581.